Novel HPLC-based assay for measuring thymidine kinase activity as a cancer biomarker

Nikolai Zhelev, Elena Kuzmanova, Marilena Spanou

    Research output: Contribution to journalMeeting Abstract

    Abstract

    Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring thymidine kinase activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. The TK assay has been evaluated with samples from breast cancer patients.
    Original languageEnglish
    Pages (from-to)S81
    Number of pages1
    JournalJournal of Biotechnology
    Volume256
    Issue numbersuppl
    Early online date16 Aug 2017
    DOIs
    Publication statusPublished - 30 Aug 2017
    EventEuropean biotechnology Congress 2017 - Rixos Libertas, Dubrovnik, Croatia
    Duration: 25 May 201727 May 2017
    http://eurobiotech2017.eu/?p=Home

    Fingerprint Dive into the research topics of 'Novel HPLC-based assay for measuring thymidine kinase activity as a cancer biomarker'. Together they form a unique fingerprint.

  • Cite this